Short answer
ARVINAS, INC. (ARVN) filed an 8-K current report with the SEC on May 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Rigel receives exclusive global VEPPANU rights, assuming launch and U.S. commercialization responsibilities.
ARVINAS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Rigel receives exclusive global VEPPANU rights, assuming launch and U.S. commercialization responsibilities
- Arvinas and Pfizer split $70.0M upfront, $15.0M transition payment, and up to $320.0M milestone payments evenly
- Arvinas and Pfizer retain tiered worldwide royalties ranging from mid-teens to mid-20s
- Rigel contributes up to $40.0M toward ongoing development, reducing near-term funding burden
- Closing remains subject to Hart-Scott-Rodino waiting-period clearance; transaction is not yet effective
Item 7.01 · Regulation FD Disclosure
- May 12, 2026 press release disclosed entry into a License Agreement
- Material terms and strategic implications are contained in Exhibit 99.1
- License Agreement disclosure may affect Arvinas’ partnership economics and future development plans
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARVINAS, INC. 8-K filings
Get the next ARVN 8-K as it lands
Follow ARVN for push alerts, or ask the research agent what this filing means.